Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) have been given a consensus recommendation of “Buy” by the seven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $7.22.
INO has been the topic of several recent research reports. Cantor Fitzgerald initiated coverage on Inovio Pharmaceuticals in a report on Monday, March 25th. They set an “overweight” rating and a $3.62 price objective on the stock. Maxim Group reissued a “buy” rating and set a $8.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, April 3rd. Zacks Investment Research downgraded Hanger from a “hold” rating to a “sell” rating in a report on Tuesday, May 28th. HC Wainwright set a $4.00 price objective on Uranium Energy and gave the company a “buy” rating in a report on Tuesday, June 11th. Finally, BidaskClub downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 1st.
In related news, CEO Jong Joseph Kim sold 2,129,553 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $2.36, for a total transaction of $5,025,745.08. Following the completion of the transaction, the chief executive officer now directly owns 1,911,055 shares of the company’s stock, valued at approximately $4,510,089.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Laurent Humeau bought 20,000 shares of the stock in a transaction that occurred on Wednesday, June 5th. The shares were bought at an average cost of $2.50 per share, with a total value of $50,000.00. Following the completion of the transaction, the insider now owns 45,833 shares in the company, valued at $114,582.50. The disclosure for this purchase can be found here. In the last three months, insiders have sold 2,866,321 shares of company stock worth $7,055,433. 7.90% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in INO. Nikko Asset Management Americas Inc. bought a new position in Inovio Pharmaceuticals during the 1st quarter worth $12,169,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Inovio Pharmaceuticals during the 1st quarter worth $11,896,000. ARK Investment Management LLC raised its position in Inovio Pharmaceuticals by 55.4% during the 1st quarter. ARK Investment Management LLC now owns 2,929,597 shares of the biopharmaceutical company’s stock worth $10,927,000 after purchasing an additional 1,043,956 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Inovio Pharmaceuticals by 125.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,073,086 shares of the biopharmaceutical company’s stock worth $4,292,000 after purchasing an additional 596,684 shares during the last quarter. Finally, Wasatch Advisors Inc. raised its position in Inovio Pharmaceuticals by 9.6% during the 1st quarter. Wasatch Advisors Inc. now owns 5,848,410 shares of the biopharmaceutical company’s stock worth $21,815,000 after purchasing an additional 510,480 shares during the last quarter. 47.24% of the stock is owned by institutional investors and hedge funds.
Shares of INO stock traded up $0.06 during trading hours on Friday, reaching $2.99. The company’s stock had a trading volume of 465,048 shares, compared to its average volume of 1,199,747. The company’s 50 day moving average is $2.75. The firm has a market capitalization of $293.12 million, a P/E ratio of -2.85 and a beta of 2.03. Inovio Pharmaceuticals has a fifty-two week low of $2.15 and a fifty-two week high of $6.30. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 1.02.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.01). The business had revenue of $2.83 million during the quarter, compared to analyst estimates of $4.44 million. Inovio Pharmaceuticals had a negative net margin of 295.24% and a negative return on equity of 97.95%. On average, research analysts expect that Inovio Pharmaceuticals will post -1.01 EPS for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Featured Story: Futures Contract
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.